Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Posts Quarterly Earnings Results, Beats Estimates By $0.02 EPS

Key Points

• Shionogi & Co., Ltd. Unsponsored ADR reported an earnings per share (EPS) of $0.16 for the quarter, exceeding analysts' expectations of $0.14 by $0.02.
• The company's stock opened at $8.61, with a one-year trading range between a low of $6.53 and a high of $8.99.
• Shionogi specializes in pharmaceuticals, producing treatments for a variety of conditions, including HIV and COVID-19 with products like Xocova and Cabenuva.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY - Get Free Report) released its quarterly earnings data on Monday. The company reported $0.16 earnings per share for the quarter, beating analysts' consensus estimates of $0.14 by $0.02, Zacks reports. The company had revenue of $672.90 million for the quarter, compared to analysts' expectations of $719.55 million.

Shionogi & Co., Ltd. Unsponsored ADR Stock Down 0.9%

Shares of SGIOY traded down $0.08 during mid-day trading on Thursday, reaching $8.35. The company's stock had a trading volume of 87,613 shares, compared to its average volume of 106,036. Shionogi & Co., Ltd. Unsponsored ADR has a 12-month low of $6.53 and a 12-month high of $8.99. The stock has a market cap of $14.20 billion, a PE ratio of 14.30, a price-to-earnings-growth ratio of 1.91 and a beta of 0.21. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.63 and a quick ratio of 6.13. The company's 50 day moving average is $8.48 and its 200 day moving average is $7.92.

Shionogi & Co., Ltd. Unsponsored ADR Company Profile

Shionogi & Co, Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug.